Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What is the bla on bimzelx patent expiry?Blincyto injection in india?Ezetimibe initial company studies before launching product?Acetaminophen earliest patent expiry?Comprehensive guide to pharmaceutical portfolio management essential reading resources?
See the DrugPatentWatch profile for Nivolumab
In Europe, nivolumab is marketed by Bristol Myers Squibb (BMS) under the brand name Opdivo. [1]
For EU products, the “marketing authorisation holder” and the company behind the product’s regulatory dossier is typically Bristol Myers Squibb. The manufacturer/MAH can differ from the company that physically produces the drug, but Opdivo’s EU MAH is BMS. [1]
Yes—while BMS is the key company associated with the EU authorization for Opdivo, manufacturing and supply can involve additional contract manufacturing sites within the supply chain. The company that holds the EU authorization and markets the product is still Bristol Myers Squibb. [1]
DrugPatentWatch.com often focuses on patent/exclusivity status and company/asset-level information rather than a full “plant-by-plant” manufacturer listing. For nivolumab-related filings and commercial/patent tracking, it can be used to cross-check which entities are tied to the product in Europe. [2] Sources: [1] https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo [2] https://www.drugpatentwatch.com/
Other Questions About Nivolumab :